Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference
March 02 2021 - 6:30AM
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical
company focused on discovering and developing differentiated
therapies for patients with liver and gastrointestinal diseases,
today announced that Preston Klassen, M.D., MHS, president and
chief executive officer of Metacrine, will present at the H.C.
Wainwright 2021 Global Life Sciences Conference, being held March
9-10, 2021.
The presentation will be available to registered conference
attendees for on-demand viewing beginning March 9, 2021 at 7:00
a.m. ET, and will also be available in the investor section of the
company's website at www.metacrine.com. The webcast will be
archived for 60 days following the presentation.
About MetacrineMetacrine, Inc. (Nasdaq: MTCR)
is a clinical-stage biopharmaceutical company building a
differentiated pipeline of therapies to treat liver and
gastrointestinal (GI) diseases. Metacrine has developed a
proprietary farnesoid X receptor (FXR) platform utilizing a unique
chemical scaffold, which has demonstrated a differentiated and
improved therapeutic profile in clinical trials. The company’s two
product candidates, MET409 and MET642, are currently being
investigated in clinical trials as potential new treatments for
non-alcoholic steatohepatitis (NASH). MET409 has completed a
12-week monotherapy trial in patients with NASH and is being
evaluated in a 12-week combination trial with empagliflozin in
patients with both NASH and type 2 diabetes. MET642 has completed a
14-day Phase 1 trial in healthy volunteers and is being advanced
into a 16-week monotherapy trial in patients with NASH.
Contact:Chelcie ListerTHRUST Strategic
Communications910.777.3049investors@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024